🏛️ Verified NIH Record • Updated 2026-02-18
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients (NCT07225738)
🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: City of Hope Medical Center
🩺 Plain-English Summary (8th-Grade Level)
This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy. It also evaluates the potential benefits and harms of cannabis use.
Who can join: Review the eligibility criteria below.
Location: CTCA at Western Regional Medical Center — Goodyear, Arizona
Age range: 18 Years
🧪 Interventions in This Study
- Non-Interventional Study (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- CTCA at Western Regional Medical Center — Goodyear, Arizona
- City of Hope Medical Center — Duarte, California
- City of Hope Seacliff — Huntington Beach, California
- City of Hope at Irvine Lennar — Irvine, California
- City of Hope at Long Beach Elm — Long Beach, California
- City of Hope at Newport Beach Fashion Island — Newport Beach, California
- City of Hope South Pasadena — South Pasadena, California
- City of Hope Upland — Upland, California
- City of Hope West Covina — West Covina, California
- City of Hope Atlanta Cancer Center — Newnan, Georgia
- City of Hope at Chicago — Zion, Illinois
📞 Contact the Study Coordinator
Phone: (949) 671-4091
Email: RichLee@coh.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.